PRESS RELEASE: IVI Releases Public Feedback and Technical Expert Panel Recommendations for Open-Source Platform Model to Assess Outcomes and Value of Rheumatoid Arthritis Therapies

Priorities Emerged Which Will Shape Version 2.0 of IVI’s RA Model Los Angeles, CA – September 20, 2018 -- The Innovation and Value Initiative (IVI) today released public feedback and recommendations from its Technical Expert Panel (TEP), an objective third party comprised of five leaders in health economics, epidemiology, rheumatology, and patient communities, which the [...]

2021-03-23T19:04:34-04:00September 20th, 2018|News, Press, Publications|

IVI Releases Public Feedback on Open-Source Value Project Model for Rheumatoid Arthritis

Today, the Innovation and Value Initiative (IVI) released public feedback on the IVI Open-Source Value Project model for rheumatoid arthritis. IVI launched the Open-Source Value Project, a first-of-its-kind effort to better measure value in health care treatments, with the release of an open-source tool focused on measuring value in treatments for RA. The IVI-RA model [...]

2020-03-19T15:46:03-04:00April 16th, 2018|News, Publications|

IVI Report Examines Imbalances in Health Care Effectiveness Analyses

A new Innovation and Value Initiative (IVI) report found that cost-effectiveness analyses (CEAs) are disproportionately conducted on pharmaceutical interventions compared to other health care treatments. Learn more about what causes this and the potential policy solutions to achieve better overall balance of CEAs across health care interventions. Read more about the project and results here.

2020-03-19T15:46:21-04:00February 21st, 2018|News, Publications|

IVI Releases Protocol for Report on Cost-Effectiveness Analysis in Health Care

IVI released the research protocol for its first project, which examines the quality of evidence and methods used in cost-effectiveness analysis (CEA) in healthcare. The research protocol is available here. This is the first research project in a series that will look at issues of relevance to policy, value assessment practices or methods, economic questions related [...]

2020-03-19T15:47:00-04:00June 14th, 2017|News, Publications|

Budget Criteria And Drug Value Assessments: A Case Of Apples and Oranges?

While the details of value measurement continue to be vigorously debated, nearly unprecedented consensus has emerged over the need to align reimbursement and utilization with value. More controversial, however, is the role of budgetary criteria in determining value and in governing access to health care technologies. The case for adding budgetary tests to measure value [...]

2017-07-03T23:25:51-04:00September 22nd, 2016|Publications, Viewpoints|

Rapid Biomedical Innovation Calls for Similar Innovation In Pricing and Value Measurement

Advances in foundational science, technology, and clinical knowledge are driving a revolution in patient care. At the same time, spending on these innovative drugs and devices has increased dramatically. The question is, what—if anything—should be done to regulate this innovation? To balance physician prescribing of state-of-the-art drugs and patient desires to access them with the [...]

2017-07-14T07:27:08-04:00September 16th, 2016|Publications, Viewpoints|

IVI and Health Affairs Launch New Featured Topic Series on Health Affairs Blog

Health Affairs blog, in collaboration with IVI, today launched a new featured topic series titled “Drugs and Medical Innovation.” As Health Affairs blog editor Chris Fleming notes in an introductory post, the areas of drugs and medical innovation “have long been central in health care and health policy, and recent developments have heightened their importance even more. The [...]

2020-03-19T15:47:35-04:00September 15th, 2016|News, Publications|

Does a ‘One-Size-Fits-All’ Formulary Policy Make Sense

Over the last decade, insurers have increasingly used step therapy or “fail-first,” policies as a strategy to contain pharmaceutical costs. Step therapy requires patients to begin treatment for a medical condition on a typically less expensive drug, and only progress to more costly second-line drugs when the first-line therapy becomes ineffective or inappropriate. Step therapy [...]

2017-07-03T22:25:18-04:00June 2nd, 2016|Publications, Viewpoints|

Utility of Cancer Value Frameworks for Patients, Payers, and Physicians

This viewpoint, authored by Dr. Chandra, Dr. Shafrin, and Dr. Dhawan, describes the differences between various cancer value frameworks and provides recommendations for improving them for clinicians, patients, and payers. In recent years, novel cancer therapies have improved the expected survival of patients but have also increased treatment costs. As a result of these increases, [...]

2017-07-03T23:06:26-04:00May 17th, 2016|Publications, Viewpoints|
Go to Top